Check the exorbitant price of zolgensma and other orphan drugs.

ORPHAN drugs; SPINAL muscular atrophy; SCHOOL children

(Bloomberg Opinion) -- Check the Exorbitant Prices of "Orphan Drugs": Peter B. Bach By 2020, drugs with at least one orphan indication are expected to consume one-third of the U.S. drug budget, according to the Foundation for Research on Equal Opportunity. Thanks to unconstrained pricing for orphan treatments, along with the raft of financial benefits embedded in the Orphan Drug Act, the best minds in drug development are being lured away from research on prevalent diseases. [Extracted from the article]

Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)